Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis

OBJECTIVE: Mirikizumab, a monoclonal antibody targeting the interleukin-23 p19 subunit, was effective in a Phase 2 study (NCT02589665) of moderately-to-severely active ulcerative colitis (UC). We studied mirikizumab’s impact on health-related quality of life (HRQoL). DESIGN: HRQoL was evaluated usin...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubinsky, Marla C, Jairath, Vipul, Feagan, Brian G, Naegeli, April N, Tuttle, Jay, Morris, Nathan, Shan, Mingyang, Arora, Vipin, Lissoos, Trevor, Agada, Noah, Hibi, Toshifumi, Sands, Bruce E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069555/
https://www.ncbi.nlm.nih.gov/pubmed/37001911
http://dx.doi.org/10.1136/bmjgast-2023-001115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069555/
https://www.ncbi.nlm.nih.gov/pubmed/37001911
http://dx.doi.org/10.1136/bmjgast-2023-001115

Ejemplares similares